Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

Ads

You May Also Like

CymaBay Therapeutics to Present at Two Investor Conferences

NEWARK, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage ...